Table 3 Survival probabilities from the model outcomes and trial data
| Â | Model outcome | Trial data | Difference |
|---|---|---|---|
Disease-free survival | Â | Â | Â |
 Surgery only at 3 years | 60.8% | 59.6% (95% CI, 54.9 - 64.3%) | 1.2% |
 Adjuvant with S-1 at 3 years | 72.3% | 72.2% (95% CI, 67.9 - 76.4%) | 0.1% |
 Adjuvant with XELOX strategy at 3 years | 75.0% | 74% (95% CI, 69 - 79%) | 1.0% |
 Surgery only at 5 years | 51.2% | 53.1% (95% CI, 48.7 - 57.4%) | −1.9% |
 Adjuvant with S-1 at 5 years | 64.6% | 65.4% (95% CI, 61.2 - 69.5%) | −0.8% |
 Adjuvant with XELOX strategy at 5 years | 67.9% | 68% | −0.1% |
Overall survival | Â | Â | Â |
 Surgery only at 3 years | 72.2% | 70.1% (95% CI, 65.5 - 74.6%) | 2.1% |
 Adjuvant with S-1 at 3 years | 80.4% | 80.1% (95% CI, 76.1 - 84.0%) | 0.3% |
 Adjuvant with XELOX strategy at 3 years | 80.7% | 83% (95% CI, 79 - 87%) | −2.3% |
 Surgery only at 5 years | 60.9% | 61.1% (95% CI, 56.8 - 65.3%) | −0.2% |
 Adjuvant with S-1 at 5 years | 71.8% | 71.7% (95% CI, 67.8 - 75.7%) | 0.1% |
 Adjuvant with XELOX strategy at 5 years | 72.1% | 78% | −5.9% |